TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05897515

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: LIAISON NES FLU A/B & COVID-19
Description: The LIAISON® NES FLU A/B \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
Study: NCT05429671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Participants will have total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Participants will have total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Participants will have total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Participants will have total knee arthroplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
Study: NCT05946720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training including aggression and the use of BVC.
Description: After obtaining verbal consent from the nurses who met the inclusion criteria of the study before the pre-test was applied to the nurses, the nurses who volunteered to participate in the study were randomized within their own clinic using the simple randomization method. For this, after the data collection form was distributed before the pre-test, the nurses were asked to write the letter that came to them on the data collection form and not forget it. In order for nurses to be included in the training or comparison group, the letter A, written on the closed papers in the box prepared for simple randomization, represents the Education group, and the letter B represents the comparison group.
Study: NCT05050747

Intervention type: DRUG
Intervention: hCG
Description: endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction
Study: NCT05010876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Inhibitor Human
Description: standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Inhibitor Human
Description: standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant Injection
Description: a single injection of 30 mg subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
Study: NCT05429671

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic cement spacer
Description: participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
Study: NCT04589728

Intervention type: DRUG
Intervention: Venetoclax plus HMA
Description: patients with AML, ineligible for intensive chemotherapy, treated with the combination of HMA plus venetoclax under the Italian Law N. 648/96.
Study: NCT06448949

Intervention type: OTHER
Intervention: Flow Diverter Implantation
Description: Patients must undergo flow diverter implantation and have DSA examinations of the parent artery and TCCD examinations of Flow Diverter Implantation performed preoperatively, three days postoperatively, and six months postoperatively.
Study: NCT04846192

Intervention type: OTHER
Intervention: Nutritional evaluation
Description: Collecting existing data on pre operative nutritional status and outcomes after surgery
Study: NCT05023538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling
Description: Exercise on bicycle ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling
Description: Exercise on bicycle ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling
Description: Exercise on bicycle ergometer
Study: NCT03997097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomised in the group placebo in 3 oral doses of per day
Study: NCT04689945

Intervention type: DRUG
Intervention: Morphine
Description: PREOPERATIVE ANALGESIA: None~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Morphine 0,1 mg/kg IV~POSTOPERATIVE ANALGESIA IV Morphine Patient-Controlled Analgesia (PCA) Rescue analgesic: IV paracetamol

Intervention type: PROCEDURE
Intervention: Erector Spinae Block
Description: PREOPERATIVE ANALGESIA:~Ultrasonography (USG) guided ESP block:T4 spinal level, %0,25 concentration 20 ml, single injection~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol

Intervention type: DRUG
Intervention: Control
Description: PREOPERATIVE ANALGESIA: none~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol
Study: NCT05017428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermidine
Description: Spermidine in the form of a 0.1% spermidine wheat germ extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermidine
Description: Spermidine in the form of a 0.1% spermidine wheat germ extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermidine
Description: Spermidine in the form of a 0.1% spermidine wheat germ extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Nicotinamide given as niacinamide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Nicotinamide given as niacinamide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Nicotinamide given as niacinamide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA
Description: Palmitoylethanolamide given at 98% purity

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA
Description: Palmitoylethanolamide given at 98% purity

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA
Description: Palmitoylethanolamide given at 98% purity

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OEA
Description: Oleoylehtanolamide given at 90% purity

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OEA
Description: Oleoylehtanolamide given at 90% purity

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OEA
Description: Oleoylehtanolamide given at 90% purity

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Flour
Description: Wheat flour given as a placebo control
Study: NCT05114343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform weight-bearing exercises for 12 weeks. The intervention will be delivered remotely through video calling with an exercise specialist.
Study: NCT04808076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shunt surgery
Description: Shunt operation
Study: NCT05183568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: Self-guided bibliotherapy (specific chapters to read each week) and daily use of a meditation app for 45 minutes
Study: NCT05727215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 subunit protein recombinant vaccine
Description: SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
Study: NCT05783908

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: With non-magnetic screen
Description: Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing
Study: NCT05985226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraoral scan
Description: All the experimental groups will be developed with an intraoral scanner, a device that emits light and collects the image projected by that light, to build a 3-dimensional digital model. It is more comfortable than conventional impressions and it is a harmless, non-intrusive, and painless procedure.
Study: NCT05049135

Intervention type: DEVICE
Intervention: Somnofy® sleep monitor
Description: Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)

Intervention type: DEVICE
Intervention: Somnofy® sleep monitor
Description: Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
Study: NCT05362045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days
Study: NCT04745975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized treatment guided by mini-PDX and RNA sequencing
Description: Personalized treatment guided by mini-PDX and RNA sequencing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8, 15, q4w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2, d1,8 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine 25mg/m2 d1,8, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2, d1,8, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1250 mg/m2 bid po
Study: NCT05497544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise recommendation group
Description: A verbal exercise recommendation will be provided. This recommendation will be reported also in the hospital resignation letter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise recommendation plus guidebook group
Description: This group will receive the exercise (verbal and written) recommendation. Additionally, the oncologist hand the patient a guidebook about exercise, specifically designed for cancer patients.
Study: NCT05902325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 MG Injection
Description: Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
Study: NCT05693298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
Study: NCT05645601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-NK
Description: The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10\^6/kg, 2x10\^7/kg) after FC chemotherapy.
Study: NCT04472884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mWACh-PrEP
Description: Participants randomized to mWACh-PrEP will be registered into the system, in addition to receipt of SOC services. Women registered into the mWACh-PrEP platform will indicate their preferences for message delivery including a preferred name for messaging, language (English or Kiswahili or Dholuo), and day of the week and time for SMS delivery. Once registered, women will receive weekly automated push messages on the day/time of their choice from enrollment through 6-months postpartum. All automated push messages will include participant nickname, clinic and nurse name, an educational message or actionable advice targeting PrEP adherence and continuation and/or maternal and child health (MCH) topics, and a question related to the content. SMS topics will include adherence encouragement, PrEP efficacy and safety, self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications) and visit reminders.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: All participants will receive SOC services for MCH and PrEP that will include health education, clinical assessments, laboratory safety monitoring, STI (syphilis, gonorrhea, and chlamydia) screening and treatment (including expedited partner treatment for
Study: NCT05851248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal muco-gingival tissue graft
Description: Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation. The incisions will be made in the same way as in the recipient area, including both papillae. The vertical incision will measure the distance from the cementoenamel junction (CEJ) to the bony dehiscence in the GR tooth, plus at least 2 mm. The tissue between the incisions will be elevated fjull or partial thickness close to the bone in the keratinized portion and superficially in the mucosal portion. A soft tissue substitute will be adapted and sutured to protect the donor site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal connective tissue graft
Description: Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation A connective tissue graft will be taken from the palatal area, at the level of the premolars, which will include the two papillae. The size of the graft will be the same as that of the recipient area. A soft tissue substitute will be adapted and sutured to protect the donor site, especially if there is exposed bone.
Study: NCT04978337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilematovir
Description: Rilematovir 250 mg will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to rilematovir will be administered orally.
Study: NCT06420817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indian version of a 'Portfolio' diet
Description: The participants will be required to follow the prescribed diet plan for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The participants will be required to join for an hour of group online exercise program 3 days a week for 4 weeks~• (Exercise Duration = 180 minutes per week including cardio, strength training and flexibility)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The participants will be required to do intermittent fasting for 12 hours daily for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring of sleep and stress levels
Description: The participants will be required to monitor their sleep and stress levels
Study: NCT06072118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenomedullin
Description: Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
Study: NCT06337357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: Progressive resistance training includes face-to-face education on resistance training:~Resistance exercises with elastic bands include 9 exercises for 1 course. During the first 4 weeks, the patient exercises twice a week with a level of exertion according to Borg's category-ratio 10 (CR10) scale of 4-5 points. For the next 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 6-7 points. In the last 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 8-9 points.~The three-month intervention involves twelve weekly calls, with a focus on building rapport (e.g. providing feedback on the baseline assessment); education reinforcement on resistance training; and skill-building (e.g. self-monitoring and resistance training diary). The emphasis is on helping participants to gain the knowledge and skills necessary to achieve targeted intensity. Every 4 weeks, all patients are re-visited by investigators in the hospital.
Study: NCT05433545

Intervention type: OTHER
Intervention: Questionnaire
Description: Adolescents with spinal deformity will be asked to fill out a new questionnaire measuring the quality and quantity of adherence to specific physiotherapy exercises performed at home. Patients will be recruited at an outpatient service dedicated to the treatment of vertebral deformities during the monthly sessions with the physiotherapist
Study: NCT05029687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth-Led Hypertension Education Digital Intervention
Description: The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
Study: NCT05418465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwu decoction
Description: Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin, 10mg at a time, once a day. Oral administration.
Study: NCT06357624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization
Description: The SNAGS technique was applied to 3 sets of 10 repetitions with 15-30 seconds rest between sets while the participants were in a sitting position. A physiotherapist applied passive motion to facet joints at each spinal level. The participant was questioned in which direction he/she felt pain during cervical ROM and the application was carried out in the painful/limited directions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Mobilization
Description: For the self-mobilization technique, each participant was asked to extend a pain-free while pushing upwards from the transverse processes of the treated vertebra with the thumbs of both hands. In addition, the middle or index finger of the right hand was asked to pull the treated vertebra to the right side, while at the same time, left rotation was asked at the pain limit. Self-mobilization was applied every day, twice a day, five times.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-Mobilization
Description: For the self-mobilization technique, each participant was asked to extend a pain-free while pushing upwards from the transverse processes of the treated vertebra with the thumbs of both hands. In addition, the middle or index finger of the right hand was asked to pull the treated vertebra to the right side, while at the same time, left rotation was asked at the pain limit. Self-mobilization was applied every day, twice a day, five times.
Study: NCT04786691

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Addition of half and half to coffee
Description: 1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Addition of half and half to coffee
Description: 1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Addition of half and half to coffee
Description: 1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Addition of non-dairy creamer to coffee
Description: 1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Addition of non-dairy creamer to coffee
Description: 1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Addition of non-dairy creamer to coffee
Description: 1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Black
Description: No Creamer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black
Description: No Creamer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black
Description: No Creamer